Cambridge Investment Research Advisors
ABCL icon

Cambridge Investment Research Advisors’s AbCellera Biologics ABCL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,705
Closed -$41K – 3461
2024
Q3 		$41K Sell
15,705
-8,463
-35% -$23.4K ﹤0.01% 3343
2024
Q2 		$72K Sell
24,168
-6,637
-22% -$25.1K ﹤0.01% 3190
2024
Q1 		$140K Sell
30,805
-821
-3% -$4.19K ﹤0.01% 3101
2023
Q4 		$181K Sell
31,626
-2,709
-8% -$12.6K ﹤0.01% 2933
2023
Q3 		$158K Sell
34,335
-408
-1% -$2.48K ﹤0.01% 2882
2023
Q2 		$224K Sell
34,743
-1,675
-5% -$11.4K ﹤0.01% 2782
2023
Q1 		$275K Sell
36,418
-6,800
-16% -$61.7K ﹤0.01% 2561
2022
Q4 		$438K Sell
43,218
-1,954
-4% -$22.6K ﹤0.01% 2118
2022
Q3 		$447K Buy
45,172
+1,565
+4% +$17.2K ﹤0.01% 2028
2022
Q2 		$464K Sell
43,607
-3,361
-7% -$28.5K ﹤0.01% 2013
2022
Q1 		$458K Buy
46,968
+1,205
+3% +$11.4K ﹤0.01% 2182
2021
Q4 		$654K Buy
45,763
+3,355
+8% +$50.9K ﹤0.01% 1891
2021
Q3 		$850K Buy
42,408
+15,526
+58% +$274K ﹤0.01% 1655
2021
Q2 		$591K Buy
+26,882
New +$741K ﹤0.01% 1923

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cambridge Investment Research Advisors's ABCL Position: Q4 2024 in Review

Cambridge Investment Research Advisors sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 15,705 shares — an estimated $41K sold.

Cambridge Investment Research Advisors first reported a position in ABCL in Q2 2021 and held it in 14 quarters. The position peaked at $850K in Q3 2021. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • Cambridge Investment Research Advisors reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 15,705 AbCellera Biologics shares in Q4 2024, an estimated $41K.
  • Cambridge Investment Research Advisors first reported a position in AbCellera Biologics in Q2 2021 and held it in 14 quarters.
  • Cambridge Investment Research Advisors's AbCellera Biologics position peaked at $850K in Q3 2021.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.